KEAP1 and non-small cell lung carcinoma: And targeting STING with DMXAA, a STING agonist, is sufficient to improve innate and adaptive immune signaling in Kelch-like ECH-associated protein 1 (KEAP1)-mutant NSCLC tumors, which are frequently resistant to immunotherapy47.